Research ExplorerPublicationsPrognostic value of the systemic immune-inflammation index i...

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer

Standard

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. / Katayama, Satoshi; Mori, Keiichiro; Pradere, Benjamin; Laukhtina, Ekaterina; Schuettfort, Victor M; Quhal, Fahad; Motlagh, Reza Sari; Mostafaei, Hadi; Grossmann, Nico C; Rajwa, Pawel; Moschini, Marco; Mathieu, Romain; Abufaraj, Mohammad; D'Andrea, David; Compérat, Eva; Haydter, Martin; Egawa, Shin; Nasu, Yasutomo; Shariat, Shahrokh F; European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group.

In: WORLD J UROL, Vol. 39, No. 12, 12.2021, p. 4355-4361.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Katayama, S, Mori, K, Pradere, B, Laukhtina, E, Schuettfort, VM, Quhal, F, Motlagh, RS, Mostafaei, H, Grossmann, NC, Rajwa, P, Moschini, M, Mathieu, R, Abufaraj, M, D'Andrea, D, Compérat, E, Haydter, M, Egawa, S, Nasu, Y, Shariat, SF & European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group 2021, 'Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer', WORLD J UROL, vol. 39, no. 12, pp. 4355-4361. https://doi.org/10.1007/s00345-021-03740-3

APA

Katayama, S., Mori, K., Pradere, B., Laukhtina, E., Schuettfort, V. M., Quhal, F., Motlagh, R. S., Mostafaei, H., Grossmann, N. C., Rajwa, P., Moschini, M., Mathieu, R., Abufaraj, M., D'Andrea, D., Compérat, E., Haydter, M., Egawa, S., Nasu, Y., Shariat, S. F., & European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group (2021). Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. WORLD J UROL, 39(12), 4355-4361. https://doi.org/10.1007/s00345-021-03740-3

Vancouver

Katayama S, Mori K, Pradere B, Laukhtina E, Schuettfort VM, Quhal F et al. Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. WORLD J UROL. 2021 Dec;39(12):4355-4361. https://doi.org/10.1007/s00345-021-03740-3

Bibtex

@article{4a57410e445448009c557891712aaafe,
title = "Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer",
abstract = "PURPOSE: We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) METHODS: In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.RESULTS: Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23-2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42-4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57-7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70-14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.CONCLUSION: Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.",
author = "Satoshi Katayama and Keiichiro Mori and Benjamin Pradere and Ekaterina Laukhtina and Schuettfort, {Victor M} and Fahad Quhal and Motlagh, {Reza Sari} and Hadi Mostafaei and Grossmann, {Nico C} and Pawel Rajwa and Marco Moschini and Romain Mathieu and Mohammad Abufaraj and David D'Andrea and Eva Comp{\'e}rat and Martin Haydter and Shin Egawa and Yasutomo Nasu and Shariat, {Shahrokh F} and {European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group}",
note = "{\textcopyright} 2021. The Author(s).",
year = "2021",
month = dec,
doi = "10.1007/s00345-021-03740-3",
language = "English",
volume = "39",
pages = "4355--4361",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer

AU - Katayama, Satoshi

AU - Mori, Keiichiro

AU - Pradere, Benjamin

AU - Laukhtina, Ekaterina

AU - Schuettfort, Victor M

AU - Quhal, Fahad

AU - Motlagh, Reza Sari

AU - Mostafaei, Hadi

AU - Grossmann, Nico C

AU - Rajwa, Pawel

AU - Moschini, Marco

AU - Mathieu, Romain

AU - Abufaraj, Mohammad

AU - D'Andrea, David

AU - Compérat, Eva

AU - Haydter, Martin

AU - Egawa, Shin

AU - Nasu, Yasutomo

AU - Shariat, Shahrokh F

AU - European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group

N1 - © 2021. The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - PURPOSE: We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) METHODS: In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.RESULTS: Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23-2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42-4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57-7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70-14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.CONCLUSION: Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.

AB - PURPOSE: We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) METHODS: In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.RESULTS: Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23-2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42-4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57-7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70-14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.CONCLUSION: Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.

U2 - 10.1007/s00345-021-03740-3

DO - 10.1007/s00345-021-03740-3

M3 - SCORING: Journal article

C2 - 34143284

VL - 39

SP - 4355

EP - 4361

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 12

ER -